Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc (HOLX) delivers innovative healthcare solutions through diagnostic imaging systems and surgical technologies focused on women’s health. This dedicated news hub provides investors and industry professionals with essential updates directly from the company and verified sources.
Access timely Hologic press releases, earnings reports, and strategic announcements in one centralized location. Track developments across key business segments including diagnostic systems, breast health technologies, and minimally invasive surgical solutions. Our curated feed ensures you never miss regulatory filings, product approvals, or partnership announcements impacting this medical technology leader.
This resource serves as your primary source for monitoring Hologic’s advancements in healthcare diagnostics and operational milestones. Content is rigorously verified to maintain factual accuracy while avoiding speculative analysis. Bookmark this page for efficient tracking of HOLX’s progress in developing technologies that enhance clinical decision-making worldwide.
Hologic, Inc. (Nasdaq: HOLX) announced Q2 fiscal 2024 results, with revenue of $1,017.8M, GAAP EPS $0.72, Non-GAAP EPS $1.03, exceeding guidance. Total company organic revenue growth was 4.9% in constant currency. The company raised full-year revenue midpoint and EPS guidance.
Hologic, Inc. (Nasdaq: HOLX) announced the acquisition of Endomagnetics for $310 million, enhancing their breast surgery portfolio with innovative technologies. The deal is expected to expand options for breast cancer procedures, increase global access to advanced solutions, and improve patient care. Endomag's revenue in 2023 was approximately $35 million. The acquisition will be slightly dilutive to Hologic's non-GAAP earnings per share in 2024, break even in 2025, and accretive thereafter.
